Modulation of tryptase release from human tonsil mast cells by protease inhibitors

Pharmacological Reports

Volumn 57, Issue 4, 2005, Pages 523-530

  He, Shaoheng ^a,b   Xie, Hua ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Anti IgE; Histamine; Mast cell; Protease inhibitor; Tryptase

Indexed keywords

ANTIALLERGIC AGENT; ANTIINFLAMMATORY AGENT; CALCIMYCIN; CHYMASE INHIBITOR; HISTAMINE; IMMUNOGLOBULIN E; KETONE DERIVATIVE; N ALPHA 4 TOSYL LEVO LYSINE CHLOROMETHYL KETONE; N TOSYL LEVO PHENYLALANINE CHLOROMETHYL KETONE; PROTAMINE; PROTEINASE INHIBITOR; TRYPTASE; TRYPTASE INHIBITOR; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; ENZYME INHIBITION; ENZYME RELEASE; HISTAMINE RELEASE; HUMAN; HUMAN CELL; INCUBATION TEMPERATURE; INCUBATION TIME; INFLAMMATORY DISEASE; MAST CELL; TONSIL;

EID: 24744438034     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Augusto C, Lunardi LO, Vugman I: Non cytotoxic guinea-pig mesenteric mast cell stimulation by protamine. Agents Actions, 1987, 22, 185-188.
2. Augusto C, Lunardi LO, Vugman I: Reduction in rat mesentery mast cell staining after degranulation by protamine. A competitive antagonism. Cell Mol Biol, 1990, 36, 357-361.
3. Bettiol J, Radermecker M, Sele J, Henquet M, Cataldo D, Louis R: Airway mast-cell activation in asthmatics is associated with selective sputum eosinophilia. Allergy, 1999, 54, 1188-1193.
4. Brockow K, Abeck D, Hermann K, Ring J: Tryptase concentration in skin blister fluid from patients with bullous skin conditions. Arch Dermatol Res, 1996, 288, 771-773.
5. Broide DH, Gleich GJ, Cuomo AJ, Coburn DA, Federman EC, Schwartz LB, Wasserman SI: Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway. J Allergy Clin Immunol, 1991, 88, 637-648.
6. Buckley M, Walters C, Brander M, Wong WM, Cawley MI, Ren S, Schwartz LB et al.: Mast cell activation in arthritis: detection of tryptase, histamine and eosinophil cationic protein in synovial fluid. Clin Sci, 1997, 93, 363-370.
7. Butchers PR, Vardey CJ, Johnson M: Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung. Br J Pharmacol, 1991, 104, 672-676.
8. Carroll NG, Mutavdzic S, James AL: Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma. Thorax, 2002, 57, 677-682.
9. Coskun N, Sindel M, Elpek GO: Mast cell density, neuronal hypertrophy and nerve growth factor expression in patients with acute appendicitis. Folia Morphol, 2002, 61, 237-243.
10. Foreman JC, Mongar JL, Gomperts BD: Calcium ionophores and movement of calcium ions following the physiological stimulus to a secretory process. Nature, 1973, 245, 249-251.
11. Hallgren J, Estrada S, Karlson U, Alving K, Pejler G: Heparin antagonists are potent inhibitors of mast cell tryptase. Biochemistry, 2001, 40, 7342-7349.
12. He S, Chen P, Chen HQ: Modulation of enzymatic activity of human mast cell tryptase and chymase by proteinase inhibitors. Acta Pharmacol Sin, 2003, 24, 923-929.
13. He S, Gaça MDA, McEuen AR, Walls AF: Inhibitors of chymase as mast cell stabilising agents: the contribution of chymase in the activation of human mast cells. J Pharmacol Exp Ther, 1999, 291, 517-523.
14. He S, Gaça MDA, Walls AF: A role for tryptase in the activation of human mast cells: Modulation of histamine release by tryptase and inhibitors of tryptase. J Pharmacol Exp Ther, 1998, 286, 289-297.
15. He S, Gaça MD, Walls AF: The activation of synovial mast cells: modulation of histamine release by tryptase and chymase and their inhibitors. Eur J Pharmacol, 2001, 412, 223-229.
16. He S, McEuen AR, Blewett SA, Li P, Buckley MG, Leufkens P, Walls AF: The inhibition of mast cell activation by neutrophil lactoferrin: uptake by mast cells and interaction with tryptase, chymase and cathepsin G. Biochem Pharmacol, 2003, 65, 1007-1015.
17. He S, Xie H, He YS: Induction of tryptase and histamine release from human colon mast cells by IgE-dependent or -independent mechanisms. World J Gastroenterol, 2004, 10, 319-322.
18. Hultsch T, Ennis M, Heidtmann HH: The effect of serine esterase inhibitors on ionophore-induced histamine release from human pulmonary mast cells. Agents Actions, 1988, 23, 198-200.
19. Jarjour NN, Calhoun WJ, Schwartz LB, Busse WW: Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with increased airway obstruction. Am Rev Respir Dis, 1991, 144, 83-87.
20. Jones NL, Roifman CM, Griffiths AM, Sherman P: Ketotifen therapy for acute ulcerative colitis in children: a pilot study. Dig Dis Sci, 1998, 43, 609-615.
21. KleinJan A, McEuen AR, Dijkstra MD, Buckley MG, Walls AF, Fokkens WJ: Basophil and eosinophil accumulation and mast cell degranulation in the nasal mucosa of patients with hay fever after local allergen provocation. J Allergy Clin Immunol, 2000, 106, 677-686.
22. Krishna MT, Chauhan A, Little L, Sampson K, Hawksworth R, Mant T, Djukanovic R et al.: Inhibition of mast cell tryptase by inhaled APC366 attenuates allergen-induced late-phase airway obstruction in asthma. J Allergy Clin Immunol, 2001, 107, 1039-1045.
23. Macfarlane AJ, Kon OM, Smith SJ, Zeibecoglou K, Khan LN, Barata LT, McEuen AR et al.: Basophils, eosinophils, and mast cells in atopic and nonatopic asthma and in late-phase allergic reactions in the lung and skin. J Allergy Clin Immunol, 2000, 105, 99-107.
24. Marshall JK, Irvine EJ: Ketotifen treatment of active colitis in patients with 5-aminosalicylate intolerance. Can J Gastroenterol, 1998, 12, 273-275.
25. McEuen AR, He S, Brander ML, Walls, AF: Guinea pig lung tryptase: localisation to mast cells and characterisation of the partially purified enzyme. Biochem Pharmacol, 1996, 52, 331-340.
26. 2 release from mast cells of human lung, tonsil, and skin. Allergy, 1994, 49, 246-253.
27. Okayama Y, Church MK: Comparison of the modulatory effect of ketotifen, sodium cromoglycate, procaterol and salbutamol in human skin, lung and tonsil mast cells. Int Arch Allergy Appl Immunol, 1992, 97, 216-222.
28. Samoszuk M, Corwin M, Hazen SL: Effects of human mast cell tryptase and eosinophil granule proteins on the kinetics of blood clotting. Am J Hematol, 2003, 73, 18-25.
29. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T: Tryptase levels as an indicator of mast cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med, 1987, 316, 1622-1626.
30. Tremaine WJ, Brzezinski A, Katz JA, Wolf DC, Fleming TJ, Mordenti J, Strenkoski-Nix LC et al.: Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Pharmacol Ther, 2002, 16, 407-413.
31. Vassimon CS, Rothschild AM: Compound 48/80-induced secretion of histamine from rat peritoneal mast cells depends on a tryptase controlled step also leading to chymase activity. Agents Actions, 1990, 30, 150-152.
32. Walls AF, Bennett AR, Godfrey RC, Holgate ST, Church MK: Mast cell tryptase and histamine concentrations in bronchoalveolar lavage fluid from patients with interstitial lung disease. Clin Sci, 1991, 81, 183-188.
33. Walls AF, He S, Buckley MG, McEuen AR: Roles of the mast cell and basophil in asthma. Clin Exp Allergy Rev, 2001, 1, 68-72.
34. Yanagida M, Fukamachi H, Takei M, Uzumaki H, Saito TT, Iikura Y, Nakahata T: Effect of a chymotrypsin-like inhibitor, TPCK, on histamine release from cultured human mast cells. J Pharm Pharmacol, 1997, 49, 537-541.